1. Home
  2. Blog
  3. Healthcare Provider
  4. PRIME Meta Analysis

PRIME Meta Analysis

Blog, Healthcare Provider, Home Feature Healthcare Provider

In 2022, the United States Department of Veterans Affairs (VA) undertook the Precision Medicine in Mental Health Care, or PRIME Care study, the largest pharmacogenomic randomized controlled trial in mental health. They enrolled nearly 2000 veterans with depression at sites throughout the country to test whether access to GeneSight® Test results affected medication selection and improved treatment outcomes for patients with major depressive disorder (MDD).

Published in the Journal of the American Medical Association (JAMA) in 2022, the study found patients whose clinicians had access to GeneSight Test results were significantly more likely to achieve remission over 24 weeks compared to treatment as usual. Additionally, access to GeneSight Test results impacted prescribing, as patients in the treatment as usual arm were more likely to be prescribed medications with significant gene-drug interactions compared to patients in the GeneSight Test arm.

In a collaborative effort between VA investigators and Myriad, a post-hoc analysis of the PRIME Care trial was performed, which explored whether having access to the GeneSight Test results increased the rate of remission and response over time in patients with MDD, and if the effect was persistent.

Published in the Oct. 30, 2025 edition of Frontiers in Pharmacology, the new post-hoc analysis showed that patients in the GeneSight Test arm were at any given time during the 24-week study period relative to patients receiving treatment as usual:
• 27% more likely to achieve remission from depression
• 21% more likely to experience response (at least a 50% reduction in depressive symptoms)
• led to faster initial remission and response in patients.
• Further, the post-hoc analysis showed that this benefit persisted over six months with no evidence of changing over time.

“Every single day matters to someone suffering from depression; patients want to get back to feeling like themselves as quickly as possible. As a result, a long trial-and-error period with medication can be frustrating for both clinicians and patients,” said Dale Muzzey, chief scientific officer, Myriad Genetics. “This post-hoc analysis shows that treatment informed by the GeneSight Test led to faster initial remission and response in patients with MDD – and this benefit lasted for at least six months.”

Disclaimer: Not all patients who receive the GeneSight Psychotropic Test will achieve response and/or remission or have faster initial response and/or remission, and not all patients will have a persistent effect.

Myriad Genetics plans to submit these data to payers as part of its ongoing efforts to increase patient access to the GeneSight Test and to help patients achieve remission from depression.

READ MORE:

New VA Study With Gene Test for Mental Health Medications

New VA study finds access to the GeneSight® test impacted treatment decisions and improved depression remission rates

PRIME Care Study Shows Patients Whose Clinicians Had Access to the GeneSight® Test Are More Likely to Achieve Remission from Depression

Our articles are for informational purposes only and are reviewed by our Medical Information team, which includes PharmDs, MDs, and PhDs. Do not make any changes to your current medications or dosing without consulting your healthcare provider.

The GeneSight test must be ordered by and used only in consultation with a healthcare provider who can prescribe medications. As with all genetic tests, the GeneSight test results have limitations and do not constitute medical advice. The test results are designed to be just one part of a larger, complete patient assessment, which would include proper diagnosis and consideration of your medical history, other medications you may be taking, your family history, and other factors.

If you are a healthcare provider and interested in learning more about the GeneSight test, please contact us at 855.891.9415. If you are a patient, please talk with your doctor to see if the GeneSight test may be helpful.

Published: February 11, 2026
Healthcare Provider

PRIME Meta Analysis

In 2022, the United States Department of Veterans Affairs (VA) undertook the Precision Medicine in Mental Health Care, or PRIME Care study, the largest phar...

Read more

    Learn more

    Learn more about GeneSight
    How to talk to your provider
    View our clinical studies

    Take the next step with the GeneSight test

    Take a step closer to getting the GeneSight test or registering to provide the test to your patients. We will follow up with additional information either via email or phone.

    The GeneSight test must be ordered by a registered clinician. If you are a patient, caregiver or office staff who would like a clinician to be registered to administer the GeneSight test, please include their name and contact information.

    If you are a current registered provider or tested patient, please contact us.

    Take the Next Step - PD

    1. Step 1
    2. Step 2
    3. Step 3
    Please provide us with your name



    1. Step 1
    2. Step 2
    3. Step 3
    Please provide contact and clinic information
    Please provide contact information

    We are asking for Date of Birth for data verification purposes.










    We are asking for Date of Birth for data verification purposes.

    If you do not have a clinician, we have a directory of healthcare providers who are registered to order the GeneSight test. When you complete this form, we will link you to this directory, so you will have the option to view registered GeneSight providers in your area.







    Your clinician who is currently managing your medication and making treatment decisions can order your GeneSight test.

    If you do not have a clinician, we have a directory of healthcare providers who are registered to order the GeneSight test. When you complete this form, we will link you to this directory, so you will have the option to view registered GeneSight providers in your area.

    Please provide your clinician's information
    The GeneSight test must be ordered by your clinician








    1. Step 1
    2. Step 2
    3. Step 3

    How can we help?
    When completed, we'll follow up with more information
    Please let us know how we can best help you
    When completed, we'll follow up with more information


    Already taken the GeneSight test and need access to your results?








    Contact Information

    By submitting this form, you authorize Myriad to contact you about your inquiry via email and/or phone (including SMS/text message). Additionally, please note communications may be unsecure and carry typical risks associated with such transmissions. By submitting this form, you also acknowledge that you understand the foregoing warning and understand the typical risk of email and phone transmissions. For further information on our privacy practices, including information about opting-out of communications for Myriad, please visit our Privacy Notice and Notice of Privacy Practices.

    Chat